In line with all global organizations, Clinigen continues to actively monitor the developing situation with COVID-19. We are following the guidelines set out by the WHO, government, and health authorities. We also need to adhere to any government decisions made on COVID-19.
For our business continuity and ability to maintain our service, we are maintaining an awareness internally around managing risk, providing appropriate support in all our regional offices, and monitoring business travel requirements globally. Wherever possible, employees are guided to work from home and utilize VC/TC technology for meetings. For client visits, we are starting to manage in-house meetings for visitors coming from countries without a travel warning status, of course, always following the necessary safety and hygiene measures. This is to protect our team members as well as our clients. We still offer virtual tours and audits at certain sites to assist in meeting critical timelines.
In relation to outbound and inbound movement of products, we continue to monitor all regions & countries impacted by COVID-19 on a daily basis. We are working closely with our courier network to identify any alternate lanes which can be utilized where there may be a risk in product delivery to the investigators and, ultimately, patients. The movement of products and materials in and out of India has been hampered by the closure of the entire country. Where we source comparators and co-therapy medicines, these are, predominantly, from US and EU manufacturers that have, likewise, not reported issues to this effect yet. Still, we are expecting some product shortages and delivery delays. The couriers across the industry have indicated they are applying a corona surcharge to shipments.
For your projects and studies, there is no impact on supporting your patients’ needs at this time. However, please take into consideration that the worldwide and country-specific situation is changing on a daily/hourly basis, and shipments may be delayed due to the travel restrictions and border closures, airlines cancelling flights, trucks waiting at borders, etc. So, in general, we should all consider additional delays for and/or during shipping. Our Project Managers will contact you to review resupply strategies. Shipping requests should be sent earlier to allow more time for potential delays or delivery difficulties.
Clinigen Clinical Supplies Management is also supporting several COVID-19 studies with very short timelines, in addition to studies that require a hybrid model for Direct-to-Patient support, including depot to patient and site to patient shipments. We will continue to provide regular updates on projects unless something specific needs to be addressed and shared. Of course, all Project Managers will update their customer contacts on new information or any potential risk for a specific project.
As a leading provider on a global scale, Clinigen is committed to delivering fully integrated logistics services to our clients. Over 80% of the studies we are supporting are multi-national and we organise shipments to 110+ countries.